Cargando…

TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia

TP53 mutations have been associated with anaplasia in Wilms tumour, which conveys a high risk for relapse and fatal outcome. Nevertheless, TP53 alterations have been reported in no more than 60% of anaplastic tumours, and recent data have suggested their presence in tumours that do not fulfil the cr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wegert, Jenny, Vokuhl, Christian, Ziegler, Barbara, Ernestus, Karen, Leuschner, Ivo, Furtwängler, Rhoikos, Graf, Norbert, Gessler, Manfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653929/
https://www.ncbi.nlm.nih.gov/pubmed/29085664
http://dx.doi.org/10.1002/cjp2.77
_version_ 1783273308723085312
author Wegert, Jenny
Vokuhl, Christian
Ziegler, Barbara
Ernestus, Karen
Leuschner, Ivo
Furtwängler, Rhoikos
Graf, Norbert
Gessler, Manfred
author_facet Wegert, Jenny
Vokuhl, Christian
Ziegler, Barbara
Ernestus, Karen
Leuschner, Ivo
Furtwängler, Rhoikos
Graf, Norbert
Gessler, Manfred
author_sort Wegert, Jenny
collection PubMed
description TP53 mutations have been associated with anaplasia in Wilms tumour, which conveys a high risk for relapse and fatal outcome. Nevertheless, TP53 alterations have been reported in no more than 60% of anaplastic tumours, and recent data have suggested their presence in tumours that do not fulfil the criteria for anaplasia, questioning the clinical utility of TP53 analysis. Therefore, we characterized the TP53 status in 84 fatal cases of Wilms tumour, irrespective of histological subtype. We identified TP53 alterations in at least 90% of fatal cases of anaplastic Wilms tumour, and even more when diffuse anaplasia was present, indicating a very strong if not absolute coupling between anaplasia and deregulation of p53 function. Unfortunately, TP53 mutations do not provide additional predictive value in anaplastic tumours since the same mutation rate was found in a cohort of non‐fatal anaplastic tumours. When classified according to tumour stage, patients with stage I diffuse anaplastic tumours still had a high chance of survival (87%), but this rate dropped to 26% for stages II–IV. Thus, volume of anaplasia or possible spread may turn out to be critical parameters. Importantly, among non‐anaplastic fatal tumours, 26% had TP53 alterations, indicating that TP53 screening may identify additional cases at risk. Several of these non‐anaplastic tumours fulfilled some criteria for anaplasia, for example nuclear unrest, suggesting that such partial phenotypes should be under special scrutiny to enhance detection of high‐risk tumours via TP53 screening. A major drawback is that these alterations are secondary changes that occur only later in tumour development, leading to striking intratumour heterogeneity that requires multiple biopsies and analysis guided by histological criteria. In conclusion, we found a very close correlation between histological signs of anaplasia and TP53 alterations. The latter may precede development of anaplasia and thereby provide diagnostic value pointing towards aggressive disease.
format Online
Article
Text
id pubmed-5653929
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56539292017-10-30 TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia Wegert, Jenny Vokuhl, Christian Ziegler, Barbara Ernestus, Karen Leuschner, Ivo Furtwängler, Rhoikos Graf, Norbert Gessler, Manfred J Pathol Clin Res Original Articles TP53 mutations have been associated with anaplasia in Wilms tumour, which conveys a high risk for relapse and fatal outcome. Nevertheless, TP53 alterations have been reported in no more than 60% of anaplastic tumours, and recent data have suggested their presence in tumours that do not fulfil the criteria for anaplasia, questioning the clinical utility of TP53 analysis. Therefore, we characterized the TP53 status in 84 fatal cases of Wilms tumour, irrespective of histological subtype. We identified TP53 alterations in at least 90% of fatal cases of anaplastic Wilms tumour, and even more when diffuse anaplasia was present, indicating a very strong if not absolute coupling between anaplasia and deregulation of p53 function. Unfortunately, TP53 mutations do not provide additional predictive value in anaplastic tumours since the same mutation rate was found in a cohort of non‐fatal anaplastic tumours. When classified according to tumour stage, patients with stage I diffuse anaplastic tumours still had a high chance of survival (87%), but this rate dropped to 26% for stages II–IV. Thus, volume of anaplasia or possible spread may turn out to be critical parameters. Importantly, among non‐anaplastic fatal tumours, 26% had TP53 alterations, indicating that TP53 screening may identify additional cases at risk. Several of these non‐anaplastic tumours fulfilled some criteria for anaplasia, for example nuclear unrest, suggesting that such partial phenotypes should be under special scrutiny to enhance detection of high‐risk tumours via TP53 screening. A major drawback is that these alterations are secondary changes that occur only later in tumour development, leading to striking intratumour heterogeneity that requires multiple biopsies and analysis guided by histological criteria. In conclusion, we found a very close correlation between histological signs of anaplasia and TP53 alterations. The latter may precede development of anaplasia and thereby provide diagnostic value pointing towards aggressive disease. John Wiley and Sons Inc. 2017-08-14 /pmc/articles/PMC5653929/ /pubmed/29085664 http://dx.doi.org/10.1002/cjp2.77 Text en © 2017 The Authors The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Wegert, Jenny
Vokuhl, Christian
Ziegler, Barbara
Ernestus, Karen
Leuschner, Ivo
Furtwängler, Rhoikos
Graf, Norbert
Gessler, Manfred
TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
title TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
title_full TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
title_fullStr TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
title_full_unstemmed TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
title_short TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
title_sort tp53 alterations in wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5653929/
https://www.ncbi.nlm.nih.gov/pubmed/29085664
http://dx.doi.org/10.1002/cjp2.77
work_keys_str_mv AT wegertjenny tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT vokuhlchristian tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT zieglerbarbara tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT ernestuskaren tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT leuschnerivo tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT furtwanglerrhoikos tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT grafnorbert tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia
AT gesslermanfred tp53alterationsinwilmstumourrepresentprogressioneventswithstrongintratumourheterogeneitythatarecloselylinkedbutnotlimitedtoanaplasia